Treatment of Lingular Branch Pulmonary Embolism
Initial Assessment and Management
- The European Society of Cardiology recommends risk stratifying the patient based on hemodynamic stability to determine the appropriate treatment approach 1, 3
- The European Society of Cardiology suggests initiating anticoagulation therapy as soon as possible while the diagnostic workup is ongoing, unless bleeding or absolute contraindications exist 1, 4
- Assess for signs of right ventricular dysfunction and hemodynamic instability, which would indicate high-risk PE requiring more aggressive intervention 1, 2
Anticoagulation Therapy
- The European Society of Cardiology prefers a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) such as apixaban, rivaroxaban, edoxaban, or dabigatran over traditional LMWH-VKA regimen for hemodynamically stable patients 2, 4
- If NOACs are contraindicated, the European Society of Cardiology recommends using low molecular weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH) 2
- For patients transitioning to vitamin K antagonists (VKAs), overlap with parenteral anticoagulation until INR reaches 2.0-3.0 (target 2.5) 2
Special Considerations for Lingular PE
- Subsegmental PE (which may include lingular branch PE) should be carefully evaluated as there is controversy regarding clinical significance 1, 4
- The location in the lingula does not fundamentally change the treatment approach compared to other locations of PE 1, 2
Duration of Treatment
- The European Society of Cardiology recommends administering therapeutic anticoagulation for at least 3 months for all patients with PE 2
- For first PE secondary to a major transient/reversible risk factor, the European Society of Cardiology suggests discontinuing anticoagulation after 3 months 2
- Continue anticoagulation indefinitely for patients with recurrent VTE not related to a major transient/reversible risk factor 2